{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:58:09Z","timestamp":1784548689701,"version":"3.55.0"},"reference-count":29,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Neoadjuvant systemic therapy is the preferred treatment approach for stage II\u2013III HER2-positive breast cancer (BC). Real-life data comparing regimens with or without anthracyclines combined with two HER2 drugs is lacking. We compared the efficacy and toxicity of two commonly used regimens. Methods: Retrospective data were collected on patients newly diagnosed with clinical stage II\u2013III HER2-positive BC and treated at Sheba Medical Center, Israel, between September 2017 and June 2022 with either neoadjuvant DCbHP (docetaxel, carboplatin, trastuzumab, pertuzumab) or ACTHP (doxorubicin, cyclophosphamide, paclitaxel trastuzumab pertuzumab). PCR (pathological complete response) (ypT0\/isN0) was evaluated in both cohorts and according to HER2 immunohistochemistry (IHC) staining (3+ or 2+ and fluorescence in situ hybridization [FISH] positive), estrogen receptor (ER), tumor size and nodal status. The toxicity indices evaluated were reductions in left ventricle ejection fraction (LVEF), dose reductions, hospitalizations and febrile neutropenia. Results: Here, 106 received ACTHP and 73 received DCbHP. Median age at diagnosis, ER status, HER2 IHC (2+\/FISH pos or 3+) and nodal status were balanced. PCR occurred in 63.1% of patients, 67.0% and 57.5% in the ACTHP and DCbHP groups, respectively (p = 0.129). In patients with HER2 3+ IHC, pCR rates were significantly better with the ACTHP regimen than with DCbHP (83% vs. 62.9%, p &lt; 0.039). No difference was observed among patients with HER2 +2 IHC FISH pos. Symptomatic LVEF decrease was observed in seven patients (6.6%) receiving ACTHP vs. none (0%) receiving DCbHP (p &lt; 0.001). Conclusions: PCR rates were similar overall between ACTHP and DCbHP; however, in the HER2 3+ subgroup, ACTHP demonstrated increased efficacy. DCbHP was significantly less cardiotoxic.<\/jats:p>","DOI":"10.3390\/cancers17020250","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T04:42:08Z","timestamp":1736916128000},"page":"250","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9779-1704","authenticated-orcid":false,"given":"Amit","family":"Itay","sequence":"first","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opher","family":"Globus","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Levanon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Sella","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinat","family":"Bernstein-Molho","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Shapira","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Oedegaard","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Fourey","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav","family":"Nili Gal Yam","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","article-title":"Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2\u2013Overexpressing Breast Cancer: Results from the TECHNO Trial of the AGO and GBG Study Groups","volume":"29","author":"Untch","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","article-title":"Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience","volume":"20","author":"Seidman","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Moja, L., Tagliabue, L., Balduzzi, S., Parmelli, E., Pistotti, V., Guarneri, V., and D\u2019Amico, R. (2012). Trastuzumab Containing Regimens for Early Breast Cancer. Cochrane Database Syst. Rev., 1\u201365.","DOI":"10.1002\/14651858.CD006243.pub2"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study","volume":"104","author":"Bowles","year":"2012","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1200\/JCO.2004.01.120","article-title":"Clinical Cardiac Tolerability of Trastuzumab","volume":"22","author":"Perez","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.21037\/atm-22-4030","article-title":"Neoadjuvant Therapy with vs. without Anthracyclines for HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"Zhu","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus Trastuzumab in Combination with Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer: A Randomized Phase II Cardiac Safety Study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","article-title":"Long-Term Efficacy Analysis of the Randomised, Phase II TRYPHAENA Cardiac Safety Study: Evaluating Pertuzumab and Trastuzumab plus Standard Neoadjuvant Anthracycline-Containing and Anthracycline-Free Chemotherapy Regimens in Patients with HER2-Positive Early Breast Cancer","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"19","author":"Mandjes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_12","unstructured":"National Comprehensive Cancer Network (NCCN) (2025, January 07). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Breast Cancer Version 4.2024\u20143 July 2024. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41523-021-00342-5","article-title":"A Careful Reassessment of Anthracycline Use in Curable Breast Cancer","volume":"7","author":"Hurvitz","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1158\/1078-0432.CCR-16-2373","article-title":"Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2\/CEP17 Ratio in HER2-Amplified Early Breast Cancer","volume":"23","author":"Singer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1634\/theoncologist.2015-0101","article-title":"High HER2\/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer","volume":"21","author":"Kogawa","year":"2016","journal-title":"Oncologist"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e27632","DOI":"10.1097\/MD.0000000000027632","article-title":"Pathologic Complete Response to Neoadjuvant Anti-HER2 Therapy Is Associated with HER2 Immunohistochemistry Score in HER2-Positive Early Breast Cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dowling, G.P., Keelan, S., Toomey, S., Daly, G.R., Hennessy, B.T., and Hill, A.D.K. (2023). Review of the Status of Neoadjuvant Therapy in HER2-Positive Breast Cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1066007"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/annonc\/mdx773","article-title":"Pertuzumab, Trastuzumab, and Standard Anthracycline- and Taxane-Based Chemotherapy for the Neoadjuvant Treatment of Patients with HER2-Positive Localized Breast Cancer (BERENICE): A Phase II, Open-Label, Multicenter, Multinational Cardiac Safety Study","volume":"29","author":"Swain","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Dang, C., Ewer, M.S., Delaloge, S., Ferrero, J.-M., Colomer, R., De La Cruz-Merino, L., Werner, T.L., Dadswell, K., Verrill, M., and Eiger, D. (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers, 14.","DOI":"10.3390\/cancers14112596"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1001\/jamaoncol.2021.1371","article-title":"Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2 -Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial","volume":"7","author":"Mandjes","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S1470-2045(21)00122-4","article-title":"Chemotherapy De-Escalation Using an 18F-FDG-PET-Based Pathological Response-Adapted Strategy in Patients with HER2-Positive Early Breast Cancer (PHERGain): A Multicentre, Randomised, Open-Label, Non-Comparative, Phase 2 Trial","volume":"22","author":"Gebhart","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(24)00054-0","article-title":"3-Year Invasive Disease-Free Survival with Chemotherapy de-Escalation Using an 18F-FDG-PET-Based, Pathological Complete Response-Adapted Strategy in HER2-Positive Early Breast Cancer (PHERGain): A Randomised, Open-Label, Phase 2 Trial","volume":"403","author":"Colleoni","year":"2024","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/annonc\/mdw610","article-title":"Dual HER2-Blockade with Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer: A Subanalysis of Data from the Randomized Phase III GeparSepto Trial","volume":"28","author":"Loibl","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1200\/JCO.18.01842","article-title":"NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69\u2013GeparSepto","volume":"37","author":"Untch","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10549-020-05524-6","article-title":"A Randomized, 3-Arm, Neoadjuvant, Phase 2 Study Comparing Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCbHP), TCbHP Followed by Trastuzumab Emtansine and Pertuzumab (T-DM1+P), and T-DM1+P in HER2-Positive Primary Breast Cancer","volume":"180","author":"Masuda","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10549-024-07333-7","article-title":"Long-Term Outcomes of Neoadjuvant Trastuzumab Emtansine + Pertuzumab (T-DM1 + P) and Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCbHP) for HER2-Positive Primary Breast Cancer: Results of the Randomized Phase 2 JBCRG20 Study (Neo-Peaks)","volume":"207","author":"Takano","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.19.00882","article-title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer: Three-Year Outcomes from the Phase III KRISTINE Study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"GS03-12","DOI":"10.1158\/1538-7445.SABCS23-GS03-12","article-title":"Abstract GS03-12: Phase III Study of Adjuvant Ado-Trastuzumab Emtansine vs. Trastuzumab for Residual Invasive HER2-Positive Early Breast Cancer after Neoadjuvant Chemotherapy and HER2-Targeted Therapy: KATHERINE Final IDFS and Updated OS Analysis","volume":"84","author":"Loibl","year":"2024","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1200\/JCO.23.01428","article-title":"Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 [NRG Oncology])","volume":"42","author":"Geyer","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/250\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:28:51Z","timestamp":1759919331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/2\/250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["cancers17020250"],"URL":"https:\/\/doi.org\/10.3390\/cancers17020250","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]}}}